Clinicopathological and prognostic significance of programmed cell death ligand1 (PD-L1) expression in patients with non-small cell lung cancer: a meta-analysis
Clinicopathological and prognostic significance of programmed cell death ligand1 (PD-L1) expression in patients with non-small cell lung cancer: a meta-analysis
复制标题
DOI：
10.3978/j.issn.2072-1439.2015.02.13
复制
发表时间：
2015-03-01
影响因子：
2.5
通讯作者：
Wu, Jing-Xun
中科院分区：
文献类型：
--
作者：
Pan, Zhen-Kui;Ye, Feng;Wu, Jing-Xun
目的：程序性细胞死亡1（PD-1）及其配体PD-L1是重要的免疫检查点蛋白。有证据表明，PD-L1是一种新兴的生物标志物，可用于抗PD-1和抗PD-L1抗体在非小细胞肺癌（NSCLC）中的免疫治疗。为了研究PD-L1蛋白表达与临床病理特征的关系及其对生存结局的影响，我们进行了一项荟萃分析。方法：对电子数据库进行全面的文献检索（截至2014年7月10日）。通过综合合格数据分析PD-L1表达与临床病理特征和总生存期（OS）的相关性。结果：共纳入9项研究的1,550例NSCLC患者。合并比值比（OR）显示PD-L1高表达与肿瘤分化差相关[OR = 0.53，95%可信区间（CI）：0.39-0.72，P
Objective: Programmed cell death 1 (PD-1) and one of its ligands, PD-L1, are key immune checkpoint proteins. Evidences showed PD-L1 is an emerging biomarker for immunotherapy by anti-PD-1 and anti-PD-L1 antibody in non-small cell lung cancer (NSCLC). To investigate the association of PD-L1 protein expression with clinicopathological features and its impact on survival outcome, we conducted a meta-analysis.Methods: A comprehensive literature search of electronic databases (up to July 10, 2014) was performed. Correlation between PD-L1 expression and clinicopathological features and overall survival (OS) was analyzed by synthesizing the qualified data. Publication biases were examined.Results: A total of 1,550 NSCLC patients from 9 studies were included. The pooled odds ratios (ORs) indicated high PD-L1 expression was associated with poor tumor differentiation [OR = 0.53, 95% confidence interval (CI): 0.39-0.72, P